IDS and mucopolysaccharidosis type 2: IV idursulfase is beneficial for many of the somatic manifestations of MPS II [14–17, 19]; however, IV idursulfase does not cross the blood–brain barrier at therapeutic concentrations, so it is not able to mitigate CNS manifestations [20, 21].